AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19558010 — intervention group
Group type: COMPARATOR
Intervention: Caregiver report of having an asthma action plan (AAP)
Number of subjects: 114
Study 19558010 — intervention group
Group type: COMPARATOR
Intervention: Recent primary care physician visit
Number of subjects: 114
Study 17765472 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) methods
Number of subjects: 0
Study 17765472 — intervention group
Group type: COMPARATOR
Intervention: Serum/plasma biomarkers
Number of subjects: 0
Study 15166570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 10 microg
Number of subjects: 2
Study 15166570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 30 microg
Number of subjects: 2
Study 15166570 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg
Number of subjects: 2
Study 15166570 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.3 mg
Number of subjects: 2
Study 12002497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional blockade (IVRB) with 15 mg of guanethidine in 30 ml of 0.5% prilocaine
Number of subjects: 57
Study 12002497 — intervention group
Group type: COMPARATOR
Intervention: Serial IVRB with 30 ml of normal saline (control)
Number of subjects: 57
Study 9861128 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 35
Study 9861128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 35
Study 7881929 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 52
Study 7881929 — intervention group
Group type: COMPARATOR
Intervention: Surgery without delay
Number of subjects: 52
Study 1965420 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of itraconazole given in one single day
Number of subjects: 552
Study 1965420 — intervention group
Group type: COMPARATOR
Intervention: 200 mg twice daily for one day
Number of subjects: 552
Study 1965420 — intervention group
Group type: COMPARATOR
Intervention: 200 mg once daily for two days
Number of subjects: 552
Study 1965420 — intervention group
Group type: COMPARATOR
Intervention: 200 mg once daily for three days
Number of subjects: 552
Study 354304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (0.5 mg)
Number of subjects: 0
Study 354304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 354304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Number of subjects: 0
Study 6802327 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline (14 mg/kg twice daily)
Number of subjects: 24
Study 6802327 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 30947585 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab by continuous infusion for 4 weeks in 6‐week cycles
Number of subjects: 0
Study 30947585 — intervention group
Group type: COMPARATOR
Intervention: Standard salvage chemotherapy
Number of subjects: 0
Study 30947585 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab as later salvage
Number of subjects: 0
Study 30947585 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab and chemotherapy
Number of subjects: 0
Study 28985278 — intervention group
Group type: EXPERIMENTAL
Intervention: WATER (aquatic exercise)
Number of subjects: 24
Study 27474376 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-year nurse-led, multidomain cardiovascular intervention
Number of subjects: 3526
Study 27474376 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3526
Study 24861441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low luminance intermittent photic stimulation (IPS) in JME patients
Number of subjects: 13
Study 24861441 — intervention group
Group type: COMPARATOR
Intervention: Low luminance intermittent photic stimulation (IPS) in healthy controls
Number of subjects: 13
Study 24861441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic evaluation of BOLD signal changes related to photoparoxysmal response (PPR) in JME patients
Number of subjects: 13
Study 22810591 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus an induction regimen of antiangiogenesis and antitumor immunity (G2); induction regimen included low dose metronomic cyclophosphamide, high dose Cox‐2 inhibitor, granulocyte colony‐stimulating factor, a sulfhydryl donor, and a hemoderivative with autologous tumor antigens.
Number of subjects: 60
Study 22810591 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (G1); used as control group.
Number of subjects: 60
Study 20213592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 fps frame rate
Number of subjects: 107
Study 20213592 — intervention group
Group type: COMPARATOR
Intervention: 2 fps frame rate (control)
Number of subjects: 107
Study 17272293 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise led by an expert instructor
Number of subjects: 0
Study 17272293 — intervention group
Group type: COMPARATOR
Intervention: Talk-based support group
Number of subjects: 0
Study 14993132 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III CHF
Number of subjects: 1140
Study 14993132 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LVEF <0.20 and class III symptoms
Number of subjects: 1140
Study 14993132 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICD discharges
Number of subjects: 1140
Study 11770315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (INF + Ribavirin) for 6 months
Number of subjects: 445
Study 11770315 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (INF) for 18 months
Number of subjects: 445
Study 11770315 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone for 6 months
Number of subjects: 445
Study 9293649 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 0.5 mg
Number of subjects: 60
Study 9293649 — intervention group
Group type: COMPARATOR
Intervention: Epidural butorphanol 0.5 mg plus clonidine 75 micrograms
Number of subjects: 60
Study 7905413 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 14
Study 7905413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2825502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplements (three different types)
Number of subjects: 12
Study 2825502 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber control
Number of subjects: 12
Study 27288054 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly personalised, interactive, one-on-one feedback intervention for CAUTI diagnosis; details on dosage and duration not specified.
Number of subjects: 0
Study 27288054 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, report-style feedback intervention for hypertension care; details on dosage and duration not specified.
Number of subjects: 0
Study 25653199 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinktest plus prototype alteration
Number of subjects: 2634
Study 25653199 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinktest plus cue reminder
Number of subjects: 2634
Study 25653199 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinktest plus prototype alteration and cue reminder
Number of subjects: 2634
Study 25653199 — intervention group
Group type: COMPARATOR
Intervention: Original Drinktest
Number of subjects: 2634
Study 24621255 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID (5 µg for 4 weeks, then 10 µg ongoing)
Number of subjects: 261
Study 24621255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 22348698 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD) + Coronally Advanced Flap (CAF)
Number of subjects: 9
Study 22348698 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial Connective Tissue Graft (CTG) + Coronally Advanced Flap (CAF)
Number of subjects: 9
Study 22348698 — intervention group
Group type: COMPARATOR
Intervention: Comparison between EMD + CAF and CTG + CAF
Number of subjects: 9
Study 22348698 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Number of subjects: 9
Study 22348698 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial Connective Tissue Graft (CTG)
Number of subjects: 9
Study 22348698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction
Number of subjects: 9
Study 19430303 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS-defining events (ADEs)
Number of subjects: 368
Study 19430303 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-AIDS serious adverse events (SAEs)
Number of subjects: 368
Study 17761059 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-option for asthma reviews
Number of subjects: 1809
Study 17761059 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face-only reviews
Number of subjects: 1809
Study 17761059 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 1809
Study 16398429 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai injection (SI)
Number of subjects: 64
Study 16398429 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 64
Study 16398429 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 64
Study 11181656 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide 400 mg/m(2) IV, epirubicin 50 mg/m(2) IV, and fluorouracil 500 mg/m(2) IV on days 1 and 8)
Number of subjects: 460
Study 11181656 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 500 mg/m(2) IV, methotrexate 40 mg/m(2) IV, and fluorouracil 600 mg/m(2) IV on days 1 and 8)
Number of subjects: 460
Study 11181656 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 460
Study 11181656 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 460
Study 9710013 — intervention group
Group type: EXPERIMENTAL
Intervention: Echoplanar magnetic resonance perfusion imaging (PI)
Number of subjects: 18
Study 9710013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 18
Study 9710013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern of PI lesion larger than DWI lesion
Number of subjects: 18
Study 9710013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern of DWI lesion but no PI lesion
Number of subjects: 18
Study 7846930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing
Number of subjects: 30
Study 3059899 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline at mean concentrations of 5.13, 12.07, and 18.6 micrograms/ml
Number of subjects: 16
Study 3059899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30717227 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling based on motivational interviewing (MI) on healthy eating and physical activity
Number of subjects: 436
Study 30717227 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating alone
Number of subjects: 436
Study 30717227 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity alone
Number of subjects: 436
Study 30717227 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 436
Study 28743315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Number of subjects: 75
Study 28743315 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 75
Study 26188198 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 200
Study 26188198 — intervention group
Group type: COMPARATOR
Intervention: Control (no posterior pericardiotomy)
Number of subjects: 200
Study 23388508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FC)
Number of subjects: 61
Study 23388508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate followed by allogeneic blood products (FC+FFP)
Number of subjects: 61
Study 23388508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (FFP)
Number of subjects: 61
Study 22093569 — intervention group
Group type: EXPERIMENTAL
Intervention: CarFit intervention
Number of subjects: 195
Study 22093569 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 195
Study 19604642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (22.2±2.0 mg/h/70 kg)
Number of subjects: 60
Study 19604642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17341752 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental reporting of AOM episodes
Number of subjects: 120
Study 17341752 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental interview method
Number of subjects: 120
Study 15456342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin 50 mg/day
Number of subjects: 0
Study 15456342 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole 100 mg/day
Number of subjects: 0
Study 11552994 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin and low molecular weight heparin (dalteparin) during heparin prophylaxis at 30 weeks of gestation
Number of subjects: 20
Study 11552994 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis (regardless of type)
Number of subjects: 20
Study 11552994 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-heparin prophylaxis (4 months after delivery)
Number of subjects: 20
Study 11552994 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 pregnant women with no history of thromboembolism)
Number of subjects: 20
Study 9522143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 2% (6 mL)
Number of subjects: 44
Study 9522143 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (3 mL)
Number of subjects: 44
Study 8594693 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 600
Study 8594693 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 600
Study 8594693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar (pyrimethamine‐sulfadoxine)
Number of subjects: 600
Study 8594693 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 600
Study 2483435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d.)
Number of subjects: 45
Study 2483435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (200 mg t.i.d.)
Number of subjects: 45
Study 2483435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissively worded amnesia suggestions with hypnotic motivation
Number of subjects: 120
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritatively worded amnesia suggestions with hypnotic motivation
Number of subjects: 120
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissively worded amnesia suggestions with waking motivation
Number of subjects: 120
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritatively worded amnesia suggestions with waking motivation
Number of subjects: 120
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissively worded amnesia suggestions with waking nonmotivation
Number of subjects: 120
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritatively worded amnesia suggestions with waking nonmotivation
Number of subjects: 120
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Task motivating procedures
Number of subjects: 120
Study 4423243 — intervention group
Group type: EXPERIMENTAL
Intervention: Non task motivating procedures
Number of subjects: 120
Study 31113688 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized 3D printed models
Number of subjects: 45
Study 31113688 — intervention group
Group type: COMPARATOR
Intervention: CT & MRI imaging (care-as-usual)
Number of subjects: 45
Study 31113688 — intervention group
Group type: COMPARATOR
Intervention: 3D reconstructions
Number of subjects: 45
Study 28662692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (MB TKA)
Number of subjects: 106
Study 28662692 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (FB TKA)
Number of subjects: 106
Study 26222557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (34 to 35°C)
Number of subjects: 370
Study 26222557 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.5 to 37.5°C)
Number of subjects: 370
Study 23911260 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211
Number of subjects: 12
Study 23911260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21282130 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine scent detection of breath samples
Number of subjects: 70
Study 21282130 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine scent detection of stool samples
Number of subjects: 70
Study 19807925 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Schema Therapy (ST)
Number of subjects: 0
Study 19807925 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist telephone availability outside office hours
Number of subjects: 0
Study 19807925 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 17219155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microm every 6 h for a maximum of 24 h)
Number of subjects: 130
Study 17219155 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel (0.5 mg every 6 h for a maximum of 24 h)
Number of subjects: 130
Study 17219155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 130
Study 17219155 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel
Number of subjects: 130
Study 15650341 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (100 mg)
Number of subjects: 30
Study 15650341 — intervention group
Group type: COMPARATOR
Intervention: Estrogen replacement therapy (0.625 mg conjugated estrogen)
Number of subjects: 30
Study 11525087 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0
Study 11525087 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study 10223394 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPP mouth-rinse and dentifrice
Number of subjects: 131
Study 10223394 — intervention group
Group type: COMPARATOR
Intervention: MMPP dentifrice
Number of subjects: 131
Study 10223394 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 131
Study 10223394 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPP rinse and dentifrice with SLS
Number of subjects: 131
Study 10223394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 2026667 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (a selective beta‐2 agonist)
Number of subjects: 12
Study 2026667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (a new non‐selective beta‐blocker with beta‐2 agonist activity)
Number of subjects: 12
Study 2026667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N Saline)
Number of subjects: 12
Study 6318353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-Profenid 300 mg
Number of subjects: 44
Study 6318353 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenbutazone 400 mg
Number of subjects: 44
Study 31868813 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weekly sets per muscle group (G16)
Number of subjects: 27
Study 31868813 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weekly sets per muscle group (G24)
Number of subjects: 27
Study 31868813 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 weekly sets per muscle group (G32)
Number of subjects: 27
Study 31901649 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium group
Number of subjects: 187
Study 31901649 — intervention group
Group type: COMPARATOR
Intervention: Non-delirium group
Number of subjects: 187
Study 31226888 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dissection
Number of subjects: 376
Study 31226888 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond laser
Number of subjects: 376
Study 30217048 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic activity program
Number of subjects: 142
Study 30217048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical activity and Low Glycemic Index Mediterranean Diet (LGIMD)
Number of subjects: 142
Study 30217048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of omega-3 PUFAs with healthy lifestyle
Number of subjects: 142
Study 27488368 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented guided self-help program
Number of subjects: 110
Study 27488368 — intervention group
Group type: COMPARATOR
Intervention: Nondirective guided self-help program
Number of subjects: 110
Study 23959116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 45
Study 23959116 — intervention group
Group type: COMPARATOR
Intervention: Control CCBs
Number of subjects: 45
Study 21378215 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning carbohydrate counting
Number of subjects: 61
Study 21378215 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning carbohydrate counting (per-protocol analysis)
Number of subjects: 61
Study 21378215 — intervention group
Group type: COMPARATOR
Intervention: Estimating pre‐meal insulin dose (control)
Number of subjects: 61
Study 19637541 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy
Number of subjects: 97
Study 19637541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without shortwave diathermy)
Number of subjects: 97
Study 17567306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic care
Number of subjects: 27
Study 17567306 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 16871748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (3 x 200 mg + 400 mg after 12 h)
Number of subjects: 76
Study 16871748 — intervention group
Group type: COMPARATOR
Intervention: Single 400 mg dose of cimetidine
Number of subjects: 76
Study 16871748 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 76